First in class oncology medicine will provide new treatment option while adding to the company's late stage development portfolio PARIS and BRISBANE, Calif., April 15, 2009 Sanofi-aventis announced today that it has signed a binding agreement for the acquisition of BiPar...

First in class oncology medicine will provide new treatment option while adding to the company's late stage development portfolio PARIS and BRISBANE, Calif., April 15, 2009 Sanofi-aventis announced today that it has signed a binding agreement for the acquisition of BiPar Sciences, Inc., a privately held US biopharmaceutical company, developing ...